The Online Investor
Cytokinetics Inc (CYTK)

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure, AMG 594, a cardiac troponin activator, reldesemtiv, a skeletal muscle troponin activator for the treatments of spinal muscular atrophy and amyotrophic lateral sclerosis, and CK-3773274, a cardiac myosin inhibitor which is designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy.

CYTK SEC Filing Email Alerts Service
Company Name: 
Cytokinetics Inc
Drugs & Pharmaceuticals
Number of ETFs Holding CYTK: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
Quotes delayed 20 minutes

Strong Buy (3.64 out of 4)
59th percentile
(ranked higher than approx. 59% of all stocks covered)

Analysts' Target Price:
CYTK Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Cytokinetics Inc (CYTK) Page | The Online Investor Page |

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.